API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
ARINA-1 is a new nebulized product comprised of ascorbic acid, glutathione, and bicarbonate which is currently being investigated in phase 2 clinical trials for the treatment of patients with Non-cystic Fibrosis Bronchiectasis.
Lead Product(s): Ascorbic Acid,Glutathione,Bicarbonate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Arina-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2024
Details:
DuraGraft is a first-in-class CE marked intra-operative graft storage solution used during bypass surgeries that is authorized for use in Europe and other countries outside of the United States.
Lead Product(s): Glutathione,Ascorbic Acid
Therapeutic Area: Cardiology/Vascular Diseases Product Name: DuraGraft
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2023
Details:
EZC Pak is the proven over-the-counter rapid immune support solution that contains professional strength doses of Echinacea, zinc, vitamin C (and sometimes vitamin D). It is being indicated for the reduction in illness duration for patients with upper respiratory infections.
Lead Product(s): Echinacea,Zinc,Ascorbic Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: EZC Pak
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
ARINA-1 (ascorbic acid) is an investigational nebulized therapy to prevent the progression of bronchiolitis obliterans syndrome (BOS) progression in individuals with a bilateral lung transplant.
Lead Product(s): Ascorbic Acid,Glutathione
Therapeutic Area: Immunology Product Name: ARINA-1
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
ARINA-1 (ascorbic acid), an investigational nebulized therapy, to treat adults with non-CF bronchiectasis,has been shown to have significant mucolytic activity, as well as robust anti-inflammatory properties.
Lead Product(s): Ascorbic Acid,Glutathione
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ARINA-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
Ovaprene®, an investigational hormone-free monthly intravaginal contraceptive, prevented essentially all sperm from entering the cervical canal across all women and all cycles evaluated.
Lead Product(s): Ferrous Gluconate,Ascorbic Acid
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovaprene
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
ARINA-1 (ascorbic acid) is a first-in-class therapy that addresses deficiencies in the innate immune system that occur in chronic inflammatory airway diseases, such as non-CF bronchiectasis, COPD, and lung transplant.
Lead Product(s): Ascorbic Acid
Therapeutic Area: Immunology Product Name: ARINA-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
ARINA-1, novel nebulized therapy delivered to the lungs to treat pulmonary diseases, it clears mucus and reduces damaging inflammation in the airways to restore lung health in non-cystic fibrosis bronchiectasis.
Lead Product(s): Ascorbic Acid
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ARINA-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
New oil-free moisturizer is formulated with HA Serum (hyaluronic acid), Vitamin C and unique botanical boosters to hydrate and repair the most challenged, dry, eczema-prone skin.
Lead Product(s): Hyaluronic Acid,Ascorbic Acid,Dragon Fruit
Therapeutic Area: Dermatology Product Name: Moisture Recovery HA Serum
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
Daré and Avomeen are currently collaborating on development-stage programs, including Ovaprene®, an investigational hormone-free, monthly contraceptive, and intend to expand their partnership to include more programs in Daré’s women’s health pipeline.
Lead Product(s): Ferrous Gluconate,Ascorbic Acid
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovaprene
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avomeen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 01, 2020
Details:
The paper provides an overview of the impact of ARINA-1 on mucus transport and shows that the ARINA-1 moves mucus significantly better than currently available options in cystic fibrosis (CF).
Lead Product(s): Ascorbic Acid,Glutathione,Bicarbonate
Therapeutic Area: Genetic Disease Product Name: ARINA-1
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
The clinical trial protocol will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection.
Lead Product(s): Hydroxychloroquine Sulphate,Azithromycin,Ascorbic Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2020
Details:
Norgine signed exclusive licence and distribution agreements with Faes Farma S.A., Pharmacare Limited T/A Aspen Pharmacare and Swixx Biopharma to provide worldwide exposure to PLENVU.
Lead Product(s): Potassium Chloride,Sodium Chloride,Ascorbic Acid
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Faes Farma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 12, 2020